Perspective Therapeutics, Inc. filed a Current Report on Form 8-K on October 1, 2026, to update its corporate presentation. The filing, which includes the presentation as Exhibit 99.1, details the company's strategy and clinical data for its portfolio of radiopharmaceuticals.
The presentation outlines a strategy focused on targeted oncology, highlighting a potential addressable market of $45 billion for solid tumors. The company reports three independent clinical-stage programs: VMT-α-NET, VMT01, and PSV359.
Regarding VMT-α-NET, the company states it is a potential first-in-class 212Pb radioligand therapy targeting SSTR2 for neuroendocrine tumors. The filing notes ongoing Phase 1/2a data analysis from ASCO 2026, indicating that patient responses deepen over time. The company reports data from 68 patients treated with blood creatinine measurements showing a best-in-class safety profile.
For VMT01, the company describes it as a potential first-in-class 212Pb therapy targeting MC1R for melanoma. The filing cites preliminary anti-tumor activity observed at a 3.0 mCi dose level in an ongoing Phase 1/2a open-label trial.
The company also discusses PSV359, a potential first-in-class 212Pb therapy targeting FAP-α for advanced solid tumors. The presentation highlights improved tumor retention and ongoing open-label Phase 1/2a trial data.
Additionally, the filing details the company's platform and manufacturing capabilities, including an integrated isotope production approach for direct-to-hospital delivery and a strong intellectual property portfolio covering the radiopharmaceutical value chain.
